-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 RmvX1TinqfRr3pRuEUYcEeKoEcW6aso5HkgnD4Pk1fXO1AuUMeQ3iiGcwCUEJiWG
 17cq3EoAxV9Wp7kp3x1HbA==

<SEC-DOCUMENT>0000950123-09-021914.txt : 20090831
<SEC-HEADER>0000950123-09-021914.hdr.sgml : 20090831
<ACCEPTANCE-DATETIME>20090713174043
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-09-021914
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20090713

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOGENEX PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0000949858
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				954343413
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		1522 217TH PLACE S.E.
		CITY:			BOTHELL
		STATE:			WA
		ZIP:			98021
		BUSINESS PHONE:		4254879500

	MAIL ADDRESS:	
		STREET 1:		1522 217TH PLACE S.E.
		CITY:			BOTHELL
		STATE:			WA
		ZIP:			98021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SONUS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19950825
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
<TITLE>Correspondence</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: Helvetica,Arial,sans-serif; margin-left: .25in; width: 7.20in">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><IMG src="c87861p8786101.gif" alt="(ONCOGENEX LOGO)"><BR>
<B><I>OncoGenex Pharmaceuticals, Inc.</I></B><BR>
<I>1522 217th Place SE, Suite&nbsp;100<BR>
Bothell, WA 98021</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">July&nbsp;13, 2009
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Jeffrey P. Riedler<BR>
Assistant Director<BR>
Division of Corporation Finance<BR>
U.S. Securities and Exchange Commission<BR>
100 F Street, N.E.<BR>
Washington, D.C. 20549-7010

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><B>Re: OncoGenex Pharmaceuticals &#151; Registration Statement on </B><B>Form S-3</B><B> (File No.&nbsp;333-160251)
filed on June&nbsp;26, 2009</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">Ladies and Gentlemen,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">On behalf of OncoGenex Pharmaceuticals, Inc. (the &#147;Company&#148;), this letter responds to the
comments of the Staff of the Securities and Exchange Commission set forth in the letter dated July
9, 2009 relating to the above-referenced registration statement (the &#147;Form S-3&#148;). On behalf of the
Company, we are filing herewith Amendment No.&nbsp;1 to the Form S-3 (the &#147;Amendment&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Set forth in italicized print below are the Staff&#146;s comments, as set forth in the July&nbsp;9, 2009
comment letter, followed by the Company&#146;s responses.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%"><U><I>Incorporation by reference of </I><I>Form 8-K</I><I> filed on 06/26/09</I></U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><I>1.&nbsp;We note that you have not incorporated by reference your </I><I>Form 8-K</I><I> filed after filing of
this registration statement on June&nbsp;26, 2009. Because your </I><I>Form 8-K</I><I> filed during the waiting period
for your registration statement to become effective, a statement specifically incorporating this
Form&nbsp;8-K was required in your disclosure on page 9. Pursuant to Securities Act Forms Compliance and
Disclosure Interpretations 123.05, &#147;if a registration statement does not specifically incorporate
reports filed during the waiting period, a pre-effective amendment would be required to
incorporate&#148; it. Therefore, please file a pre-effective amendment to incorporate your </I><I>Form 8-K</I><I> into
your registration statement.</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company has amended the Form S-3 to incorporate by reference the above-noted Form 8-K.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Very truly yours,<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/S/ Stephen Anderson
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Stephen Anderson,&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">cc: Randal R. Jones, Dorsey &#038; Whitney LLP
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>c87861p8786101.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 c87861p8786101.gif
M1TE&.#EAE0`J`/<``%,@)%HA)E\C*&,C*68C*6XB)VDC*&LC*&TC*'$E*7,E
M*74D*70D*G8D*7@C*7DC*GLB*GPB*GTA+'XA+7XB+7XD+WTE,'TF,'PH,G\H
M,W\O.7<T.W8T/'HR.WHV/'PP.GPW/7XW/G\]1'\_17Q"1WY%2($I-((J-8(L
M-H$N.(`Y0($[0H`\0X!`1H!'28%)2H1+3(5.3H513X-24H1248144X555(=6
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M^OK\^OO^_OWX^OSZ^O[[^_S\_/S^_O[^_A+:-!+:(```&````!+9^```0```
M`````!+:-!+:(````````;(`X!H`1!F:N"4>G!+<O&AL:`)P```"V``"X```
M`````#X`/!+:,+(```$``SH`0U<`7$X`24\`1%,`5W,`7',`>64`=#,`;5P`
M,G,`36T`:68`=&0`+FP`;```````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````"'Y!```````+`````"5`"H`AU,@)%HA)E\C*&,C
M*68C*6XB)VDC*&LC*&TC*'$E*7,E*74D*70D*G8D*7@C*7DC*GLB*GPB*GTA
M+'XA+7XB+7XD+WTE,'TF,'PH,G\H,W\O.7<T.W8T/'HR.WHV/'PP.GPW/7XW
M/G\]1'\_17Q"1WY%2($I-((J-8(L-H$N.(`Y0($[0H`\0X!`1H!'28%)2H1+
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M_A+:-!+:(```&````!+9^```0````````!+:-!+:(````````;(`X!H`1!F:
MN"4>G!+<O&AL:`)P```"V``"X````````#X`/!+:,+(```$``SH`0U<`7$X`
M24\`1%,`5W,`7',`>64`=#,`;5P`,G,`36T`:68`=&0`+FP`;```````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````````````````C^`%T)'$BP
MH,&#"!,J7,BPH<.'$",.3#10%:10B1:9,N5*TD:.`D.%DDC28"A&C"BZ,M5)
M8*)$CTH^%(D0HRM5JD*&,I6SY:.1"VE*$BCITJ$Z=?A$`IE3)%"9$A\E$FD*
MT4971CE]A,J0T5.!36GFU"EPZT*.(A^U/-2&"`<2,T@DX<('9"*O7$M2W&2)
M3A8B-HALL7,H;]"O*UW]'#G6Z5!7A.@VQ/C(U!TK&@@0D2-)DJ`Y<?QP?(G8
M\$).'@.ER4$";HD!`6;`J032=$&:`RT5QCWPYR.M?:IP>-/P44P[1#!(B))G
M(Z=*EXQ&<EG:MD'GG/I`X<#!"Y]!>;[^;`"P!$]MZP.?JFK3IE-IC*F=P':S
M\+$K/$0&,!`2R!3J0H$$,L@AFY@B54SH)?21'3D,D$,>FVR"4R!>&*!!&N>A
MQULD,V0AR4XAN4+3)78\@0$&`M`15">J'$*%`0%HT)PI>G#AE@!&E-&?@0@F
M>-U&>!P1``S-N>+>2GC`P``5G/A(UDJ1<,"$)(SP=)>(+>$AA`,%.)#`'2)6
MYXI7Z['`0`),F"()'UIP,8<=60S`@16%&>?D=9U9P4$*:VQB$TJA%'*$!51D
MZ&,GG9A2@@^&J"1568%`48`$$3@0PVYBJO+((4\X`($&YJU)B$=JMC&`"%88
MJ-*=`AG'"1O^)$SPQ"$@,N+*2X<TT8$:AJ+W$U9,""&(K1]>Y4<2`:1P0@(>
M>%%)F`CE9$<+!9@01"!$?;21(3$0,$-_/;(J$*<#I`"'@3R%9$H@+7#`1[BL
MJE*&NY6M5)0A4!!@00$!V/"&50OEY$4!!6C@Q24MM:2M*E\88,`93=Z)&T=Z
M=)"`"^`.!(DDZW&@Q2)B&I;A'0/(H59'IAS2!0$QIO`$'EIY=%8.!33001NF
MC-12071T$(`3A_1JVE,;J5%`"C9(LHA4B=KJQPPU%)(8JSES-(@(6_"8\AD.
M-&"`"&D$S<@B]B&4L@C5>F">0#L3Q&X!,`22J,0W=92$!0DDL<C^(AFM9(D?
M1!!QQU7BYKS2(4`D<<G>G*210@0%R.#&LPH_:=`C>6#@@`DO6`5)>HH99\@/
M!=LAM&DQY50(!Q,4D'5E,05"1@LYU.71JAJ6-=`E7930W"/30I#`#&\8QY$J
M'*%DZT&FV*%Y!#C(#+I(B1PBA`48N($6T2':Q@?K!811R?AR:#$##&$$P@DG
MALR!L(\C@11_&R*P80H?3!1P0@JF\TV]3B&C0Z4B``3IM6H@C,B5"3"@!N,X
MI2P;>2!!<,*23BS&;'63A!PX8($)""$,2X@+$<K0!ZT@H@X_D$`:VK80%C)$
M9QR)B2G^((+T6<$`%M``'#81)G@M!`[^&"A`W@PXD(T\XA*2LH`;-G4(/CQF
M$X*HPV.&XA4@P8$.=B"$*1+!D<^I0A*((,0EMN4*-7``<C#H0A7.<(>@_883
M7<`!!"SPA:%HT125X(,=ZG*KE12"$%,Q$A_\$#3[P(0G@I`#(`*!DY48P@8P
M((,'"K`"-TCH(A)DR"/HH#D')(&($'3%(22E`3=(@@U+J`%/)(&%$I!@"6ZX
MA*:X^(<GK"`%*N"`$-#`"00%8@U$B,L5VM"?3:B!`!&(0!<.X1'D)<H0:H":
M!5(`!>-QP@U,>`$'9K"%PEQ"#4F8`4<.D04;<``(>MAB(\J2!RSP@`0<<`(C
M[R*)+21@!0#^Z,`:9%D24^3!`A&00/1\F!A.36`%;>!#"A+`@91E@0M]&(,!
M@/`[4]2!"`78`1S"D(`):`!;KIB##SB0@RZ`X344M<0Q)V"`5"T"+ZY`A!NR
MT$88M%02S]%"=^Y@!@Z(``Z<D(,($O`"3AQ""E_(PQB\A0B;F`(..;#!'>JP
M`@=X014I640=DJF`+4Q')J$8!`8""@-$$'0E@>A!!%(P!SU`(`(EL,0:K!`=
M-D```W4P$">@$``,@*$2<$B`!`Q@!Z,>`1PM,(]%T?:$0+1!`%R2PA;QHHI"
MW($0E7F"!IAPB&]R@`B(X$0@?I`!,UP"#A/PX"#44(5+;&(-%A#^0!U$I`H\
M\(``=WA$)9I0`!=<HBQL0$$$FD`(6_$F(I>`@00DH`(]$)0C@4@!!%HP"#VD
ME@2&6,(<\!@%R+5A;WW@0`!6T)](L0`*13EF"LJ@*DN$`7)KN`,!N#2$2SR"
M3)=`15,?(8DG,"`)A[C##`"`A<KH@71?N,0</-6"2,E!(U&X*U!=L0DI8"`&
MDLB(%@Q``DM,Z`>5HD*&O1*RLU2!2PPD7$&>RJ4GF*(/0=2H#0P!1B&8(`%J
M6!H8"#``R5+$*+]%!!$,P#^0F((.*"C`RSC`I09/%BQ&RJP%`!S8`:BA$H&`
M@T]Q9@<#F&`(:2!"(1(AB1BTC@Y-"@3^!PKP`X[I(08!@()`+C$PR,5@<,LC
MB:;D$(*:4:$2#G2*2#C1*0.L@1-Z,(`",,"$+QC"%8`@'09PQHDHY+`+'-$*
MV_1``@PXN6YY4$$!AG"'(Q`,`W3(F5<@D9.-1.('$`!"(+J0``-\H1)U:($`
MH-"?.R0``BL(@AHR7(@61"`!;%"+?!WP`]%284AU:`F[&/"$&`A@5E"6R.<.
MP8,$%*`%>0BTH`O1@0B$(&A_$&\*,!`'Q1`"!@FP0*HM\80)6,`,',E9($,=
M@14TAR*)N`,,(I<'HW')#&*C"44LLP("&H(*$&C`%,#P`@U@H2X638`#)J""
MO#X"$2M@*1W^,@('`4C@!'`P`@=@4(<OFJ(+$X`!'MB`3#-4`GF6<TCS7E``
M#W0!T'=)"7^_<*+V;,H`E?I!(3!2B2-D0`3FV<08,C"!/^_-%8N@<!<\,%Z8
MB>BI(C``%`X1"!QX^P=UD`I%AB()0E@A`0D`PB&^D`()3*`%4,"#1QY1B"U,
MRH.1@,DE?C`!#/Q!(WC(0`("D``>Q#(GU_2`"<H`"40<P0$J6*9_)/&(O<7$
MA0FQ1!DT`(`6Y+4C0]F$&TH0@,;>*A`)@!P5_!2*2DC!`#!`LRFVL`$(P(`V
M&MF(&YX0AB".H9=<[((!.'#E(W>R"7]@6R<6P0DU+$$%:#($&KS^W0(V7&)]
M5=&"#3I8@#($?B=,`#8B/&*'%=2:#,Q<IR3>\`(#4)?5:FA``3PFB-Z,)&)C
M<1!B80ADH`$&,`-J4!@4U@8D``!`8#HC<0A]AFJJ,!65H`8"$`-Y4`EN4`,U
M4&MU4`E:T1=$@`>&@`/+MR-U\`(#D`2"X!&(H`8:(`$:(`6!4""N4`A74`-L
M(`0%,`-60`(;(`!+T%D;$0A6D`1P``,0H`+-$3]ED``QT!]U,`,8D``J0`>T
MT1'1E$]H8`J-T")2$``&``!&X`;3X1P;,2H,P1.6T`8YD`(I\`-1$`5"H`&;
ME0=:82N;P`0"X`2/MG"'\`(=(`904`+^:I`'2[`!)``&@5`'3)`$=3`2@5`%
M!$`"6P`&'%`"1)`''B$S<P`$&H`!(@`$3\`$G-A&/>``<I$'==`@1\`>8)`#
M2T`80!``3/!;H5`9?S`#&T`&54`"4E`B"=`"9M`&898#[M<"01,*J$`C+Y``
M)T`P&A`$3T`%V,B)A?!;!P$)GX,;?I`&3\`#+>`",?`$:=`?O10*K'8'4G`'
M82$0=V`$/E`%<9`H;"$%P90$;#0F.[%:5E`#.<`$:M`?(K(2C-`)A[`&40`%
M0.`$5)"`;B`%*6`!5O!HEM$%2V`#29`$:R`:K@`'6\!'J@`4$TF+:A`)JA`(
MJ+0#,6`$5F#^!SU@`%W`"2>1$Y+@!BS`)0X`.0V09`9``&/'C2;1%"E118@@
M"'_`!X0P'5^T&*TF"(3#:C=Q"86@@`+Q'(9`"(;0))6A,*I0"8`@"$%S0-0Q
M+H*`9;JQ!>>4&?0Q1FK"E88P"(VT"&/T*TUQ.(4@-1CA:G\@1I%0!PD@`H'@
M$3JC6VS09S5#,`5@``*0!(.3$/$C(G<1/]HR$.[!CJX`"?5R)`01"HU11+@#
M.D-1+TUR/.D!$RNA%7=@`R10!X>@`2(0!XUDEG4#%/95-P1A.+="$9W'7QT!
M!32I8@IS"72@61:0G)YF!7F`%4+S%5^Q%2<A(K\B(E5R0>D!%(;U4ILK<26A
M5!$$\1)"YPIY0`1&H#Z'4`(E@`<[DV^WD1A/`10CP1A%5!FJL`F#0`(K,(DJ
MMA(<80ARL`58@`5<X`=[=USB<B<Y,144$0@^L`2"L#YYP`$V@)4:XA$,2`1]
M<#HWL0F24"`\E*`B6A!X80IJ8`.#H"9L@8DAFB`Q<0E2(``)%C$C6J,0`12%
M8`558(258$ZGYR,X@0A94`/;Q:&[::0V:AN?8R]_42`Q."=EDZ12.J48)`<S
M0`1?$(0`9B"L(F@E1J52.IF2$`=6$#@%V9_P`Z9J6A/:B166,`B#H!6%$8!W
0DBYK>J=XFJ=ZNJ>&$1``.S\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
